Entheon Announces Termination of Mentis AI Agreement

Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) has announced that Mentis AI (1000141080 Ontario ) has terminated the letter of intent (LOI) dated January 23, 2025.

Rhea-AI Impact

(Very High)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) has announced that Mentis AI (1000141080 Ontario ) has terminated the letter of intent (LOI) dated January 23, 2025. The LOI had outlined the terms for Entheon's proposed acquisition of all issued and outstanding common shares of Mentis AI. This termination follows the company's previous news release dated January 24, 2025.

Positive

None.

Negative

Failed acquisition attempt of Mentis AI
Termination of strategic growth opportunity

Argus Session date unavailable

+15.54% session move Open Argus

Details

News Market Reaction – ENTBF

The recorded move for ENTBF in the trading session of this news was +15.54%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/14/2025 - 05:00 PM EDT

Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that, further to its news release dated January 24, 2025, 1000141080 Ontario Ltd. ("Mentis AI") has terminated the letter of intent ("LOI") dated January 23, 2025 which set out the terms whereby Entheon would acquire all of the issued and outstanding common shares in the capital of Mentis AI.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,
Timothy Ko, CEO, President and Director

For more information, please contact the Company at:
Entheon Biomedical Corp.
Timothy Ko, CEO
1 (604) 562-3932
timothy@entheonbiomedical.com
https://entheonbiomedical.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244657

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What happened to the Entheon Biomedical (ENTBF) and Mentis AI merger agreement?

Mentis AI terminated the letter of intent (LOI) dated January 23, 2025, ending the proposed acquisition of Mentis AI by Entheon Biomedical.

When was the Entheon Biomedical (ENTBF) and Mentis AI LOI originally announced?

The LOI was dated January 23, 2025, with an initial announcement on January 24, 2025.

What was the scope of the terminated Entheon (ENTBF) acquisition deal?

The LOI outlined terms for Entheon to acquire all issued and outstanding common shares of Mentis AI (1000141080 Ontario ).

Which stock exchanges is Entheon Biomedical listed on?

Entheon Biomedical trades on the CSE (ENBI), OTCQB (ENTBF), and Frankfurt Stock Exchange (1XU).

Keep reading

Entheon Announces Termination of Mentis AI Agreement